Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
16.63(c) 15.7(c) 13.81(c) 16.54(c) 15.66(c) Last
879 548 1 062 987 4 933 410 5 415 695 1 345 293 Volume
+1.65% -5.59% -12.04% +19.77% -5.32% Change
More quotes
Estimated financial data (e)
Sales 2021 103 M 117 M 117 M
Net income 2021 -146 M -165 M -165 M
Net cash position 2021 148 M 168 M 168 M
P/E ratio 2021 -10,8x
Yield 2021 -
Sales 2022 542 M 615 M 615 M
Net income 2022 194 M 220 M 220 M
Net cash position 2022 216 M 245 M 245 M
P/E ratio 2022 8,42x
Yield 2022 -
Capitalization 1 647 M 1 868 M 1 869 M
EV / Sales 2021 14,5x
EV / Sales 2022 2,64x
Nbr of Employees 700
Free-Float 76,5%
More Financials
Company
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and has leveraged its expertise and capabilities both to successfully commercialize two vaccines and rapidly advance a broad range of vaccine candidates into... 
More about the company
Ratings of Valneva SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about VALNEVA SE
01/20Top Premarket Decliners
MT
01/20EUROPEAN MIDDAY BRIEFING - Stocks Down After Mixed Asia Trading, US Fall
DJ
01/20Valneva Gains 20% as COVID-19 Jab Shows Effect Against Omicron in Preliminary Studies
MT
01/20VALNEVA : Kepler Cheuvreux reiterates its Buy rating
MD
01/19Valneva COVID-19 Jab Shows Effect Against Omicron After Three Doses in Phase 1/2 Study
MT
01/19Valneva's Vaccine Candidate Neutralizes Omicron Variant in Early Studies; Shares Surge
MT
01/19VALNEVA : Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant - For..
PU
01/19Latest on the worldwide spread of the coronavirus
RE
01/19Valneva says early studies show COVID-19 vaccine effective against Omicron
RE
01/19Valneva says early studies show COVID-19 vaccine effective against Omicron
RE
01/19Valneva's Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
AQ
01/19Valneva SE Announces Results from an Initial Laboratory Study Demonstrating That Serum ..
CI
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/18Valneva Slips 5% As EU Drug Regulator Awaits Additional Data On COVID-19 Vaccine Candid..
MT
01/18Valneva shares dip after EU regulator comments on status of covid-19 vaccine approval
RE
More news
News in other languages on VALNEVA SE
01/21VALNEVA : parmi les plus fortes baisses du SRD à la clôture du vendredi 21 janvier 2022
01/20L'Europe finit dans le vert, les résultats des sociétés en soutien
01/20Paris finit dans le vert une séance sans tendance marquée
01/20MÄRKTE EUROPA/Erneut aufwärts - Geschäft bei Puma läuft gut
01/20AKTIEN EUROPA SCHLUSS : US-Börsen schieben die Kurse an
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Stock Trading Strategies
VALNEVA SE - 2021
Expect the comeback of a strong trend
BUY
More Stock Trading Analysis
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | MarketScreener
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 15,66 €
Average target price 22,38 €
Spread / Average Target 42,9%
EPS Revisions
Managers and Directors
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Peter Buhler Chief Financial Officer & Director
FrÚdÚric Grimaud Chairman-Supervisory Board
Michael M÷hlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-36.08%1 868
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508